- Tiziana Life Sciences ( NASDAQ: TLSA ) said it appointed Matthew Davis as chief medical officer and acting chief scientific officer, effective immediately.
- Last week, Kunwar Shailubhai had resigned as CEO, chief scientific officer and director, effective Aug. 1.
- The company said Davis has extensive experience with regulatory filings for drug approvals and device clearances.
- Davis previously served as chief scientific, and chief medical officer at Endo Pharmaceuticals Davis had also served as chief medical officer for Lupin and URL Pharma, the company noted in its July 18 press release.
- "I am thrilled to join the Tiziana team, and for the opportunity to help advance Foralumab, TZLS-501 and Milciclib," said Davis.
- Tiziana ( TLSA ) noted that Davis will report to Gabriele Cerrone, executive chairman and interim CEO.
For further details see:
Tiziana appoints former Endo exec as chief medical officer